文献速递肿瘤 PET/CT

FDG-PET/CT与增强CT在转移性乳腺癌治疗反应监测中的比较

Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-05-01

该研究纳入65例接受一线或二线全身治疗的IV期乳腺癌患者,前瞻性临床试验中分别用RECIST 1.1评估增强CT、PERCIST评估FDG-PET/CT的治疗反应。PET/CT反应对无进展生存和疾病特异性生存的预测均优于增强CT。

要点

  • RECIST应答者22例均为PERCIST应答者,RECIST非应答者中40%(17/43)为PERCIST应答者。
  • PERCIST对PFS预测一致性指数0.70 vs RECIST 0.60,PET/CT优于CE-CT。
  • PERCIST对DSS预测一致性指数0.65 vs RECIST 0.55,PET/CT优于CE-CT。

核心结论

  • 在转移性乳腺癌患者中,PET/CT的肿瘤反应对PFS和DSS的预测似乎优于CE-CT的反应评估。

研究设计与样本

  • 研究纳入65例转移性乳腺癌患者,均在接受一线或二线全身治疗的前瞻性临床试验中。
  • 采用RECIST 1.1评估CE-CT治疗反应,采用PERCIST评估FDG-PET/CT治疗反应。

主要发现

  • RECIST应答者22例全部为PERCIST应答者,RECIST非应答者43例中17例(40%)为PERCIST应答者。
  • PERCIST对PFS预测一致性指数0.70 vs RECIST 0.60。
  • RECIST应答者 vs 非应答者1年PFS为59% vs 27%;PERCIST应答者 vs 非应答者1年PFS为63% vs 0%。
  • RECIST应答者 vs 非应答者4年DSS为50% vs 38%(p=0.2,一致性指数0.55);PERCIST应答者 vs 非应答者4年DSS为58% vs 18%(p<0.001,一致性指数0.65)。

关键数值与推荐

  • RECIST 1.1用于CE-CT治疗反应评估,PERCIST用于FDG-PET/CT治疗反应评估。

临床怎么用

  • 原文结论认为PET/CT监测肿瘤反应可能提高以肿瘤反应为终点的临床试验效能,并可能改善临床常规中的患者管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to compare fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) and contrast-enhanced computed tomography (CE-CT) for the prediction of progression-free survival (PFS) and disease-specific survival (DSS) in patients with stage IV breast cancer undergoing systemic therapy. METHODS: Sixty-five patients with metastatic breast cancer treated with first- or second-line systemic therapy in prospective clinical trials were included. Response to treatment was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for CE-CT and by PET Response Criteria in Solid Tumors (PERCIST), respectively. RESULTS: All responders by RECIST (n = 22) were also responders by PERCIST, but 40% (17/43) of non-responders by RECIST were responders by PERCIST. Responses according to RECIST and PERCIST both correlated with PFS, but PERCIST showed a significantly higher predictive accuracy (concordance index for PFS: 0.70 vs. 0.60). One-year PFS for responders vs. non-responders by RECIST was 59% vs. 27%, compared to 63% vs. 0% by PERCIST. Four-year DSS of responders and non-responders by RECIST was 50% and 38%, respectively (p = 0.2, concordance index: 0.55) as compared to 58% vs. 18% for PERCIST (p < 0.001, concordance index: 0.65). Response on PET/CT was also a significantly better predictor for DSS than disease control on CE-CT. CONCLUSIONS: In patients with metastatic breast cancer, tumor response on PET/CT appears to be a superior predictor of PFS and DSS than response on CE-CT. Monitoring tumor response by PET/CT may increase the power of clinical trials using tumor response as an endpoint, and may improve patient management in clinical routine.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Riedl CC, Pinker K, Ulaner GA, et al. Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2017. PMID: 28462446. doi:10.1007/s00259-017-3703-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。